• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

    7.260 +0.425 (+6.22%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Oct 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 51,391
    Open 6.930
    Bid (Size) 7.010 (1)
    Ask (Size) 9.000 (2)
    Prev. Close 6.835
    Today's Range 6.720 - 7.445
    52wk Range 3.210 - 10.69
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
    Via Benzinga

    Performance

    YTD
    +4.31%
    +4.31%
    1 Month
    +24.74%
    +24.74%
    3 Month
    +11.69%
    +11.69%
    6 Month
    -24.06%
    -24.06%
    1 Year
    +114.79%
    +114.79%

    More News

    Read More
    Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
    Via InvestorPlace
    Coya Therapeutics to Present at Upcoming Healthcare Conferences
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
    From Coya Therapeutics, Inc.
    Via Business Wire
    COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
    From Coya Therapeutics, Inc.
    Via Business Wire
    7 Biotech Stocks to Put on Your Breakthrough Radar
    Via InvestorPlace
    EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
    Via Benzinga
    Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
    From Coya Therapeutics, Inc.
    Via Business Wire
    COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.